CD274 and neoplasm: Bodor's study reviews the biomarker PD‐L1 as well as other tissue‐ and serum‐based markers, such as cytotoxic T‐lymphocyte‐associated antigen 4, interferon γ, NK cells, and tumor‐infiltrating lymphocytes, that have the potential to better predict responders to immunotherapy.56